Eyepoint Pharmaceuticals Inc (EYPT)

Currency in USD
10.890
+0.830(+8.25%)
Closed·
After Hours
10.680-0.210(-1.93%)
·
EYPT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
EYPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.40010.920
52 wk Range
3.91013.985
Key Statistics
Prev. Close
10.06
Open
9.99
Day's Range
9.4-10.92
52 wk Range
3.91-13.985
Volume
967.38K
Average Volume (3m)
781.49K
1-Year Change
14.97%
Book Value / Share
4.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EYPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.692
Upside
+191.02%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Eyepoint Pharmaceuticals Inc Company Profile

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Employees
165

Eyepoint Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 revenue surged to $24.5M, up from $11.7M YoY, with EPS loss of $0.65 beating -$0.67 forecast
  • Operating expenses rose to $73.3M from $45M YoY, leading to a net loss of $45.2M despite revenue growth
  • Cash runway extended into 2027; Phase III DuraVu trial enrollment to complete in H2 2025, data expected H2 2026
  • Stock fell 2.4% pre-market despite earnings beat; analysts maintain strong buy consensus with ambitious targets
  • Management confident in competitive edge for DuraVu, emphasizing unique sustained delivery and new mechanism of action
Last Updated: 07/05/2025, 14:56
Read Full Transcript

Compare EYPT to Peers and Sector

Metrics to compare
EYPT
Peers
Sector
Relationship
P/E Ratio
−5.1x−0.1x−0.5x
PEG Ratio
0.150.060.00
Price/Book
2.5x1.3x2.6x
Price / LTM Sales
13.4x1.8x3.3x
Upside (Analyst Target)
167.9%99.2%43.5%
Fair Value Upside
Unlock24.1%6.3%Unlock

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 31.692
(+191.02% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.65 / -0.67
Revenue / Forecast
24.45M / 7.87M
EPS Revisions
Last 90 days

EYPT Income Statement

People Also Watch

24.03
OUST
+0.59%
213.80
LEU
+1.79%
264.75
AVAV
-1.19%
3.66
ALT
+2.23%
45.130
SMR
+4.03%

FAQ

What Stock Exchange Does Eyepoint Pharma Trade On?

Eyepoint Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Eyepoint Pharma?

The stock symbol for Eyepoint Pharma is "EYPT."

What Is the Eyepoint Pharma Market Cap?

As of today, Eyepoint Pharma market cap is 747.64M.

What Is Eyepoint Pharma's Earnings Per Share (TTM)?

The Eyepoint Pharma EPS (TTM) is -2.43.

When Is the Next Eyepoint Pharma Earnings Date?

Eyepoint Pharma will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is EYPT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Eyepoint Pharma Stock Split?

Eyepoint Pharma has split 2 times.

How Many Employees Does Eyepoint Pharma Have?

Eyepoint Pharma has 165 employees.

What is the current trading status of Eyepoint Pharma (EYPT)?

As of 05 Aug 2025, Eyepoint Pharma (EYPT) is trading at a price of 10.89, with a previous close of 10.06. The stock has fluctuated within a day range of 9.40 to 10.92, while its 52-week range spans from 3.91 to 13.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.